FY2030 Earnings Forecast for CRVS Issued By HC Wainwright

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) – Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Corvus Pharmaceuticals in a research report issued to clients and investors on Friday, March 13th. HC Wainwright analyst S. Lee anticipates that the company will post earnings per share of $0.83 for the year. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Corvus Pharmaceuticals’ current full-year earnings is ($0.63) per share.

Corvus Pharmaceuticals (NASDAQ:CRVS) last posted its earnings results on Thursday, March 12th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).

Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, January 21st. Jefferies Financial Group raised their price target on Corvus Pharmaceuticals from $13.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Barclays lifted their price target on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, January 20th. Cantor Fitzgerald reissued an “overweight” rating on shares of Corvus Pharmaceuticals in a report on Friday. Finally, Oppenheimer restated an “outperform” rating and issued a $33.00 price objective (up from $32.00) on shares of Corvus Pharmaceuticals in a research report on Friday. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Corvus Pharmaceuticals Price Performance

CRVS opened at $15.32 on Monday. The firm has a market capitalization of $1.29 billion, a P/E ratio of -30.64 and a beta of 0.79. Corvus Pharmaceuticals has a one year low of $2.54 and a one year high of $26.95. The company has a fifty day moving average price of $16.46 and a 200-day moving average price of $10.60.

Institutional Trading of Corvus Pharmaceuticals

A number of institutional investors have recently modified their holdings of CRVS. GSA Capital Partners LLP lifted its position in shares of Corvus Pharmaceuticals by 25.9% in the 3rd quarter. GSA Capital Partners LLP now owns 401,407 shares of the company’s stock worth $2,958,000 after purchasing an additional 82,675 shares during the period. BML Capital Management LLC bought a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at about $475,000. Foresite Capital Management VI LLC increased its position in shares of Corvus Pharmaceuticals by 9.5% during the second quarter. Foresite Capital Management VI LLC now owns 1,731,233 shares of the company’s stock valued at $6,925,000 after buying an additional 150,000 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in Corvus Pharmaceuticals in the second quarter worth about $49,000. Finally, NEOS Investment Management LLC bought a new position in Corvus Pharmaceuticals in the third quarter worth about $436,000. 46.64% of the stock is currently owned by hedge funds and other institutional investors.

More Corvus Pharmaceuticals News

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $33 (from $32), implying substantial upside from current levels — a clear analyst vote of confidence that can support longer‑term buying interest. Oppenheimer Rating/Price Target
• Positive Sentiment: Company announced positive safety and efficacy data from cohort 4 of soquelitinib in a Phase 1 atopic dermatitis trial, including responses in patients with prior systemic therapy — this clinical progress materially de‑risks the program and supports future value for the pipeline. Atopic Dermatitis Trial Data
• Neutral Sentiment: Corvus released its Q4 2025 results and held an earnings call; management highlighted strategic advances tied to the pipeline and provided a business update, but the call materials are a mixed read for near‑term revenue prospects. Earnings Call Highlights
• Negative Sentiment: Q4 EPS came in at ($0.15), missing consensus by $0.01 — a small miss but enough to pressure sentiment in the absence of immediate revenue drivers; this likely contributed to the intraday pullback. Earnings Miss / Transcript
• Neutral Sentiment: Reported short‑interest updates in recent days show anomalous/zero values and appear unreliable — there is no clear evidence of a near‑term short squeeze or meaningful short pressure based on the published figures. (No actionable link available.)

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.